A new generation of vaccines and boosters against SARS-CoV-2 may take a page from the anti-influenza playbook, with shots periodically tailored to target the most commonly circulating virus
Last year started out hopeful with the emergence of COVID-19 vaccines, but quickly proved to be a challenging year for governments and communities worldwide.
In places with low vaccination rates, Covid-19 has the chance to linger, and variants develop and travel. Without global vaccine equity, this entirely predictable pattern will repeat